HeartFlow(HTFL)
Focus: HeartFlow is a public biotech company specializing in AI-enabled coronary artery disease diagnostics, primarily through its flagship FFRCT imaging technology. The company operates at the intersection of cardiovascular imaging and computational diagnostics, serving a focused but critical cardiac care market.
Profile data last refreshed 19m ago · AI intelligence enriched 1mo ago
Funding Stage
PUBLIC
Open Jobs
62+15 this month
Growing — net +15 jobs in 30d
40 jobs added vs 25 removed. Steady team buildout.
Should You Work at HeartFlow?
AI assessmentHeartFlow suits early-to-mid-career professionals in software engineering, clinical data science, and commercial roles seeking a focused, well-funded diagnostic AI company, but offers limited opportunity for traditional pharma/biotech development specialists.
Why Work Here
- Public company with $123M cash runway and $87M FY2025 revenue provides stability rare in early-stage biotech while maintaining growth trajectory.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
23 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$87M
Pipeline & Clinical Trials
Heartflow PCI Navigator
Coronary Artery Disease (CAD)Clinical Trials (1)
NCT07479433The NAVIGATE-PCI Registry: A New Approach to VIew CT-derived Guidance Ahead of Stenting To Plan Efficient PCI
N/AHelp build intelligence for HeartFlow
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.